Contemporary Outcomes Following Transcatheter Edge-to-Edge Repair: 1-Year Results From the EXPAND Study

• Published in: JACC. Cardiovascular interventions Vol. 16; no. 5; p. 589
• Main Authors: Kar, Saibal, von Bardeleben, Ralph Stephan, Rottbauer, Wolfgang, Mahoney, Paul, Price, Matthew J, Grasso, Carmelo, Williams, Mathew, Lurz, Philipp, Ahmed, Mustafa, Hausleiter, Jörg, Chehab, Bassem, Zamorano, Jose L, Asch, Federico M, Maisano, Francesco
• Format: Journal Article
• Language: English
• Published: United States 13.03.2023
• Subjects: Cardiac Catheterization; Cardiomyopathies - complications; Heart Failure - complications; Heart Failure - diagnostic imaging; Heart Failure - therapy; Heart Valve Prosthesis Implantation; Humans; Mitral Valve - diagnostic imaging; Mitral Valve - surgery; Mitral Valve Insufficiency - diagnostic imaging; Mitral Valve Insufficiency - etiology; Mitral Valve Insufficiency - surgery; Prospective Studies; Quality of Life; Treatment Outcome; MitraClip; transcatheter edge-to-edge repair (TEER); mitral regurgitation; mitral valve repair
• ISSN: 1876-7605; 1876-7605
• DOI: 10.1016/j.jcin.2023.01.010

The third-generation MitraClip NTR/XTR transcatheter edge-to-edge repair system was introduced to assist in leaflet grasping with the longer clip arms of MitraClip XTR and to improve ease of use with the modified delivery catheter. The EXPAND study evaluated contemporary real-world outcomes in subjects with mitral regurgitation (MR) treated with the third-generation MitraClip NTR/XTR transcatheter edge-to-edge repair system. EXPAND is a prospective, multicenter, international, single-arm study that enrolled patients with primary MR and secondary MR at 57 centers. Follow-up was conducted through 12 months. Echocardiograms were analyzed by an echocardiographic core laboratories. Study outcomes included: MR severity, functional capacity measured by New York Heart Association functional class, quality of life measured by Kansas City Cardiomyopathy Questionnaire, heart failure hospitalizations, all-cause mortality. 1,041 patients were enrolled from April 2018 through March 2019, of which 50.5% had primary or mixed etiology. Implant success was 98.9%; 1.5 ± 0.6 clips were implanted per subject. Significant MR reduction from baseline (≥MR 3+: 56.0%) to 30 days (≤MR 1+:88.8%) was maintained through 1 year (MR ≤1+: 89.2%). A total of 84.5% and 93.0% of subjects in primary MR and secondary MR, respectively, had ≤1+ MR at 1 year. Significant improvements were observed in clinical outcomes (New York Heart Association functional class I/II in 80.3%, +21.6 improvement in Kansas City Cardiomyopathy Questionnaire score) at 1 year. All-cause mortality and heart failure hospitalizations at 1 year were 14.9% and 18.9%, respectively, which was significantly lower than previous studies. The study demonstrates treatment with the third-generation system resulted in substantial reduction of MR in a contemporary real-world practice, compared with the results of earlier EVEREST and COAPT trials.(The MitraClip® EXPAND Study of the Next Generation of MitraClip® Devices [EXPAND]; NCT03502811).